Zealand Pharma A/S (FRA:22Z)

Zealand Pharma Statistics

Total Valuation

Zealand Pharma has a market cap or net worth of EUR 4.63 billion. The enterprise value is 2.52 billion.

Market Cap	4.63B
Enterprise Value	2.52B

Important Dates

The next estimated earnings date is Thursday, February 19, 2026.

Earnings Date	Feb 19, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	70.29M
Shares Outstanding	n/a
Shares Change (YoY)	+12.73%
Shares Change (QoQ)	-1.97%
Owned by Insiders (%)	0.38%
Owned by Institutions (%)	40.82%
Float	55.74M

Valuation Ratios

The trailing PE ratio is 5.29.

PE Ratio	5.29
Forward PE	n/a
PS Ratio	3.78
PB Ratio	2.28
P/TBV Ratio	2.28
P/FCF Ratio	4.69
P/OCF Ratio	4.68
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 2.65, with an EV/FCF ratio of 2.55.

EV / Earnings	2.88
EV / Sales	2.06
EV / EBITDA	2.65
EV / EBIT	2.66
EV / FCF	2.55

Financial Position

The company has a current ratio of 14.10, with a Debt / Equity ratio of 0.03.

Current Ratio	14.10
Quick Ratio	14.10
Debt / Equity	0.03
Debt / EBITDA	0.06
Debt / FCF	0.06
Interest Coverage	233.70

Financial Efficiency

Return on equity (ROE) is 54.42% and return on invested capital (ROIC) is 35.58%.

Return on Equity (ROE)	54.42%
Return on Assets (ROA)	33.44%
Return on Invested Capital (ROIC)	35.58%
Return on Capital Employed (ROCE)	45.27%
Revenue Per Employee	2.79M
Profits Per Employee	1.99M
Employee Count	335
Asset Turnover	0.69
Inventory Turnover	n/a

Taxes

In the past 12 months, Zealand Pharma has paid 76.70 million in taxes.

Income Tax	76.70M
Effective Tax Rate	8.05%

Stock Price Statistics

The stock price has decreased by -30.44% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-30.44%
50-Day Moving Average	65.09
200-Day Moving Average	60.95
Relative Strength Index (RSI)	50.81
Average Volume (20 Days)	66

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Zealand Pharma had revenue of EUR 1.23 billion and earned 876.08 million in profits. Earnings per share was 12.27.

Revenue	1.23B
Gross Profit	1.23B
Operating Income	946.74M
Pretax Income	952.79M
Net Income	876.08M
EBITDA	948.13M
EBIT	946.74M
Earnings Per Share (EPS)	12.27

Balance Sheet

The company has 2.16 billion in cash and 54.42 million in debt, giving a net cash position of 2.11 billion.

Cash & Cash Equivalents	2.16B
Total Debt	54.42M
Net Cash	2.11B
Net Cash Per Share	n/a
Equity (Book Value)	2.03B
Book Value Per Share	28.88
Working Capital	2.07B

Cash Flow

In the last 12 months, operating cash flow was 990.05 million and capital expenditures -2.37 million, giving a free cash flow of 987.68 million.

Operating Cash Flow	990.05M
Capital Expenditures	-2.37M
Free Cash Flow	987.68M
FCF Per Share	n/a

Margins

Gross margin is 99.99%, with operating and profit margins of 77.23% and 71.47%.

Gross Margin	99.99%
Operating Margin	77.23%
Pretax Margin	77.73%
Profit Margin	71.47%
EBITDA Margin	77.35%
EBIT Margin	77.23%
FCF Margin	80.57%

Dividends & Yields

Zealand Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-12.73%
Shareholder Yield	-12.73%
Earnings Yield	18.92%
FCF Yield	21.33%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Zealand Pharma has an Altman Z-Score of 17.81 and a Piotroski F-Score of 6.

Altman Z-Score	17.81
Piotroski F-Score	6